Navigation Links
Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board
Date:6/4/2009

- Dr. Roscoe M. Moore, Jr. to join Board -

PRINCETON, N.J. and SAN DIEGO, June 4 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to the research and product discovery against life-threatening and life-altering infectious diseases, today announced the addition of Roscoe Moore Jr., D.V.M., Ph.D., D.Sc. to their Scientific Advisory Board.

"We expect Dr. Moore to contribute significantly to our already robust Scientific Advisory Board. His expertise across all areas of public health and infectious diseases will be a tremendous asset to Tobira Therapeutics," said James Sapirstein, CEO.

Dr. Moore, President, PH RockWood Corporation, Rockville, Maryland and Pretoria, South Africa, is the Former Assistant United States Surgeon General and Rear Admiral, United States Public Health Service (Retired). Until his retirement Dr. Moore, Jr. served with the United States Department of Health and Human Services (HHS) and was for the last twelve years of his career the principal person responsible for development support within the Office of the Secretary, Health and Human Services (HHS). Dr. Moore served as an Epidemic Intelligence Service Officer with the U.S. Centers for Disease Control (CDC) and Prevention. He was with the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA), before becoming Senior Epidemiologist within the National Institute for Occupational Safety and Health, CDC. He served as the Chief Epidemiologist with the Center for Devices and Radiological Health, FDA. He directed the Epidemiology and Biostatistics Program and was an Assistant Professor of Oncology within the Howard University College of Medicine Cancer Center.

Dr. Moore received his undergraduate and Doctor of Veterinary Medicine degrees from Tuskegee Institute; his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Honorary Doctor of Science degree in recognition of his distinguished public health career by Tuskegee University.

Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health and rising to the rank of Assistant United States Surgeon General (Rear Admiral, USPHS) within the Immediate Office of the Secretary, HHS. He was selected as Chief Veterinary Medical Officer, USPHS, by Surgeon General C. Everett Koop.

About Tobira Therapeutics Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.

    Contact:
    Tobira Therapeutics Inc.
    Antoinette Bobbitt
    abobbitt@tobiratherapeutics.com
    Tel: 609-897-1102
    www.tobiratherapeutics.com


'/>"/>
SOURCE Tobira Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Tobira Therapeutics Inc. Announces Senior Management Team
2. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... April 25, 2017 Providence ... licensed its novel immune-modulating technology to an undisclosed global ... allergy. Tregitopes, pronounced T·rej·itopes, are a ... by EpiVax CEO Annie De Groot ... immunoglobulin G, an autoimmune disease therapy, Tregitopes are ...
(Date:4/25/2017)... WA (PRWEB) , ... April 25, 2017 , ... Leaders ... division of Quorum, will be featured in multiple sessions at this week’s Association ... from emerging trends to best practices in clinical research. , "We are excited to ...
(Date:4/21/2017)... ... 21, 2017 , ... The 2017 Colorado Manufacturing Awards celebrates ... nominees and well as the first-year award for 2017 Manufacturing Women of the ... hosted by CompanyWeek and Manufacturers Edge, among other sponsors. , The Colorado ...
(Date:4/21/2017)... BELLINGHAM, Washington, USA (PRWEB) , ... April 21, ... ... for sensing, imaging, and related applications were the focus of researchers, engineers, product ... Sensing 2017 in Anaheim. , Sponsored by SPIE, the international society ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... 2017 The research team of The Hong ... fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery and ... speed and accuracy for use in identification, crime investigation, immigration control, ... ... A research team led ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):